Navigation Links
Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
Date:4/14/2008

cromet-inc.com" target="_new">(http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are currently in clinical trials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody MT103 is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. The second clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody which targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody, MT293 is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual result
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Announces Changes in Management Team
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
6. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
7. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
8. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
11. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  PCI is pleased to ... Biotec is a leading provider of Clinical Trial ... Bridgend, Wales in the ... significantly expands PCI,s presence in the UK/EU to ... adding packaging, storage and distribution capacity, as well ...
(Date:9/18/2014)... 18, 2014  Low T Center endorses the ... Hyattsville, Maryland earlier this ... proper patient population for testosterone therapy (TRT), as ... with TRT. Examining recent claims from studies that TRT ... epidemiological studies do not provide convincing evidence that ...
(Date:9/18/2014)... , September 18, 2014 ... Markets ( http://www.researchandmarkets.com/research/f9nkkh/sugar_alcohols ) has announced the addition ... Business Report"  report to their offering.  ... analyzes the worldwide markets for Sugar Alcohols ... Segments: Food & Confectionery, Pharmaceuticals, Cosmetics, Oral-Care ...
Breaking Medicine Technology:PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2Sugar Alcohols - Global Strategic Business Report 201 2Sugar Alcohols - Global Strategic Business Report 201 3
... Vascular Disrupting Agent and,Tubulin Inhibitor , SALT ... Inc.,(NASDAQ: MYGN) (<a target="_blank" href=,"http://www.myriad.com/">www.myriad.com ) announced ... mode of action of its,investigational new drug, ... annual meeting of the American Association for ...
... 18, 2007 - Gemin,X today announced the presentation ... lead compound, GX15-070 (obatoclax), in infant,acute lymphoblastic leukemia ... at the Annual Meeting of the American Association,for ... potent single agent activity against ALL blast cells,and ...
Cached Medicine Technology:Myriad Genetics Presents Azixa's Mode of Action at AACR 2Myriad Genetics Presents Azixa's Mode of Action at AACR 3Gemin X Presents Positive Preclinical Data of GX15-070 in Infant,ALL at AACR Meeting 2Gemin X Presents Positive Preclinical Data of GX15-070 in Infant,ALL at AACR Meeting 3
(Date:9/19/2014)... are able to grow well in infertile land, and ... reason for this is because most legumes have a ... nitrogen in the air and then supply the host ... plants create symbiotic organs called nodules in their roots. ... will adversely affect the growth of the plants, because ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Lifeinsure.biz ... life insurance riders that can be purchased without medical ... values up and make a life insurance policy more ... to find more about extra options available for a ... insurance without medical examinations required is simple to purchase, ...
(Date:9/19/2014)... York, NY (PRWEB) September 19, 2014 ... Stevie Wonder tickets for his 2014 concert tour. ... In the music business, there are a handful of artists ... Stevie Wonder. Born in Saginaw, MichIgan, Wonder has been a ... During his time in the music business, he has released ...
(Date:9/19/2014)... September 19, 2014 Dr. John Paul ... Periodontal Treatment to their Miami practice. Routinely at ... and Dr. Lamas are one of the first ... health’ approach for diagnosing and treating periodontal disease. ... most under-diagnosed and under-treated diseases in the world. ...
(Date:9/19/2014)... Steven Reinberg HealthDay Reporter ... half of all Americans got a flu shot last year, ... months and older get vaccinated for the coming flu season. ... getting the protection from flu they could get," said Dr. ... and Prevention, during a morning news conference. The result ...
Breaking Medicine News(10 mins):Health News:Long-distance communication from leaves to roots 2Health News:No Medical Exam Life Insurance - Lifeinsure.biz Presents 5 Important Riders! 2Health News:Stevie Wonder Tickets: Ticket Down Slashes Ticket Prices in Seattle, Boston, New York, Atlanta, Chicago, Detroit, Philadelphia, Toronto, Las Vegas & Oakland 2Health News:Stevie Wonder Tickets: Ticket Down Slashes Ticket Prices in Seattle, Boston, New York, Atlanta, Chicago, Detroit, Philadelphia, Toronto, Las Vegas & Oakland 3Health News:Gallardo & Lamas Periodontics & Implant Dentistry Therapeutic Periodontal Treatment Shown to Improve Patient’s Overall Health 2Health News:Gallardo & Lamas Periodontics & Implant Dentistry Therapeutic Periodontal Treatment Shown to Improve Patient’s Overall Health 3Health News:Almost Everyone Needs a Flu Shot: CDC 2Health News:Almost Everyone Needs a Flu Shot: CDC 3
... disease characterized by difficultly in breathing and the ... in these patients. Earlier research has shown that ... and endurance of respiratory muscles of COPD patients, ... found that this intense training// is difficult for ...
... of Texas has found a gene mutation in people with ... too much calcium. They reported on six gene mutations which ... much calcium absorption - a condition known as absorptive hypercalciuria ... a greater risk// for osteoporosis because of deficiencies in the ...
... hospitals to overcome illness. However, very often, patients land ... infections that they contract during their stay. Sanjay Saint, ... born infections are common, costly and harmful, but they ... which can be prevented by new and simple// changes. ...
... Chronic Obstructive Pulmonary Disease - including chronic bronchitis and ... blockage of the bronchial tubes. Asthma is a chronic ... resulting in episodes of airflow obstruction, which has been ... death and affects nearly 16 million people in the ...
... in the United States have found that the practice ... the past 14 years. However, they suggested that patients ... Helicobacter Pylori(H.Pylori) infection rather than receiving treatment for the ... more appropriate option// than empiric treatment in patients with ...
... with heart disease has shown that doctors are under-using ... these women even though the medications have been shown ... Though this study did not look at how often ... shown that men and women alike are under-treated for ...
Cached Medicine News:Health News:Adult COPD or asthma could be effectively treated with Xopenex 2Health News:Heart disease in women being under-treated 2
... Utilized for capsulotomies, nucleus ... Formed (bent) cystitomes are angled ... of the lens, providing easier ... while reducing the potential for ...
23 gauge thin wall irrigation. 25 gauge thin wall aspiration. Angled 30 degree shaft 8 mm from tip to bend. Irrigation tip set 0.5 mm behind aspiration tip. Dual hub construction. Polished finish. Ov...
U tip irrigation-aspiration cannual designed for manual removal of 12 oclock cortex. 23 gauge thin wall irrigation and aspiration lines for maximum aspiration capabilities. Polished finish. Overall l...
This specially designed 23 gauge spoon-shaped cannula is connected to a balanced salt solution bottle and with a low-flow of fluid, is designed to allow a controlled cleaning of the stromal interface...
Medicine Products: